These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21388993)

  • 1. Cardiac inotropes: current agents and future directions.
    Hasenfuss G; Teerlink JR
    Eur Heart J; 2011 Aug; 32(15):1838-45. PubMed ID: 21388993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure.
    Micheletti R; Palazzo F; Barassi P; Giacalone G; Ferrandi M; Schiavone A; Moro B; Parodi O; Ferrari P; Bianchi G
    Am J Cardiol; 2007 Jan; 99(2A):24A-32A. PubMed ID: 17239701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New positive inotropic substances--true inotropy or peripheral effects?
    Wilmshurst P
    Z Kardiol; 1988; 77 Suppl 5():103-11. PubMed ID: 3066033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
    Blair JE; Macarie C; Ruzyllo W; Bacchieri A; Valentini G; Bianchetti M; Pang PS; Harinstein ME; Sabbah HN; Filippatos GS; Gheorghiade M;
    Am J Ther; 2008; 15(3):231-40. PubMed ID: 18496261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New cardiotonic/inodilator agents: energetic aspects].
    Hasenfuss G
    Z Kardiol; 1992; 81 Suppl 4():57-63. PubMed ID: 1290307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inotropes in the management of acute heart failure.
    Petersen JW; Felker GM
    Crit Care Med; 2008 Jan; 36(1 Suppl):S106-11. PubMed ID: 18158469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapies for the management of decompensated heart failure: from bench to bedside.
    deGoma EM; Vagelos RH; Fowler MB; Ashley EA
    J Am Coll Cardiol; 2006 Dec; 48(12):2397-409. PubMed ID: 17174176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of congestive heart failure: is the role of positive inotropic therapy fading?
    Futterman LG; Lemberg L
    Am J Crit Care; 1996 Nov; 5(6):455-60. PubMed ID: 8922162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New pharmacologic therapies for acute heart failure.
    Tavares M; Rezlan E; Vostroknoutova I; Khouadja H; Mebazaa A
    Crit Care Med; 2008 Jan; 36(1 Suppl):S112-20. PubMed ID: 18158470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting SERCA2a as an innovative approach to the therapy of congestive heart failure.
    Ferrari P; Micheletti R; Valentini G; Bianchi G
    Med Hypotheses; 2007; 68(5):1120-5. PubMed ID: 17113239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure.
    Perrone SV; Kaplinsky EJ
    Int J Cardiol; 2005 Sep; 103(3):248-55. PubMed ID: 16098385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New inotropic agents in the treatment of congestive heart failure].
    Freitas M
    Rev Port Cardiol; 1993 Nov; 12 Suppl 4():19-28, 7-8. PubMed ID: 7904458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of novel inotropic agents in the treatment of heart failure.
    LeJemtel TH; Keren G; Reis D; Sonnenblick EH
    J Cardiovasc Pharmacol; 1986; 8 Suppl 9():S47-54. PubMed ID: 2433542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is calcium sensitization the best strategy to improve myocardial contractility in acute heart failure?
    Erhardt LR
    Ital Heart J; 2003 May; 4 Suppl 2():27S-33S. PubMed ID: 14635367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-blocking agents and positive inotropic agents in the therapy of chronic heart failure.
    Erdmann E; Schwinger R; Böhm M
    J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S138-44. PubMed ID: 11527118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure.
    Sabbah HN; Imai M; Cowart D; Amato A; Carminati P; Gheorghiade M
    Am J Cardiol; 2007 Jan; 99(2A):41A-46A. PubMed ID: 17239704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases.
    Kawase Y; Hajjar RJ
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):554-65. PubMed ID: 18665137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential deleterious effects of inotropic agents in the therapy of chronic heart failure.
    Katz AM
    Circulation; 1986 Mar; 73(3 Pt 2):III184-90. PubMed ID: 2417747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Congestive heart failure--pathophysiology and medical treatment.
    Remme WJ
    J Cardiovasc Pharmacol; 1986; 8 Suppl 1():S36-52. PubMed ID: 2422492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.